Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling

Samuel Taylor, Samantha Dagger, Christine Thien, Matthew Wikstrom, Wallace Langdon

Research output: Contribution to journal › Article › peer-review

36 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology

Neuroscience